/
CRVS
$14.48+$0.99 (+7.34%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$1.1B
84M shares
52-week range
$3.71 – $26.95
46% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.30%
Easy to borrow
Price (6 mo)
Loading chart…
Change+$11.81
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $847.0K | $0 | $0 | $0 | $0 | $0 | $0 | $105.0K |
| Gross profit | −$847.0K | $0 | $0 | $0 | $0 | $0 | $0 | −$105.0K |
| Gross margin | — | — | — | — | — | — | — | — |
| R&D | $38.6M | $38.0M | $31.8M | $29.1M | $24.5M | $16.5M | $19.4M | $33.7M |
| Operating income | −$49.2M | −$48.9M | −$43.8M | −$38.6M | −$32.6M | −$23.4M | −$27.5M | −$43.0M |
| EBITDA | −$46.1M | −$48.1M | −$5.4M | −$42.8M | −$40.9M | −$26.9M | −$62.2M | −$15.2M |
| Net income | −$46.9M | −$46.7M | −$6.0M | −$43.2M | −$41.3M | −$27.0M | −$62.3M | −$15.3M |
| Net margin | — | — | — | — | — | — | — | — |
| EPS (diluted) | -1.71 | -1.49 | -0.20 | -1.03 | -0.89 | -0.56 | -1.02 | -0.53 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $-200000 | $-0.68 | $-0.78–$-0.63 | 4 |
| 2027 | $5M | $-0.85 | $-0.98–$-0.72 | 4 |
| 2028 | $32M | $-0.75 | $-1.31–$-0.05 | 6 |
| 2029 | $84M | $-0.42 | $-0.42–$-0.42 | 4 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$0.02
Price
$14.48
Implied downside
-100%
Peer comparison
Corvus Pharmaceuticals, Inc.
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.
www.corvuspharma.com- Employees
- 37
- IPO / List date
- Mar 23, 2016
- HQ
- SOUTH SAN FRANCISCO, CA
Held by traders on TradeandTell
No one on the platform currently holds CRVS.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 81,310 | $1.2M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded CRVS yet.
